# Qiagen N.V. (QGEN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/QGEN
## Company Profile
- Ticker: QGEN
- Exchange: NYSE
- Sector: MedTech
- Location: Netherlands and listed in the U
- Tags: Diagnostics
## Stock Data
- Close: 43.86 USD
- Market cap: 7361062500 USD
- Last updated: 2026-09-03
## Business Overview
Qiagen is a global diagnostics and life sciences tools company focused on sample and assay technologies, molecular testing, and research workflows. Its products support research, clinical diagnostics, and applied testing.
## Why The Stock Is Moving

As of Sep 3, 2026, QGEN closed down 0.77% at $43.86. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the Netherlands and listed in the U.S. as an ADR, Qiagen has a broad international footprint. It sits in diagnostics and life sciences infrastructure rather than therapeutics.

## Business Model

The company generates revenue through consumables, assays, instrumentation, and related workflow solutions. Investors focus on molecular testing demand, lab activity, and the stability of recurring product usage.

## Landscape Position

Qiagen sits in the biotech tools and diagnostics layer. It is not a drug developer, but it is important to the ecosystem because it enables research and testing across the life sciences stack.

## Future Catalysts

- QIAGEN’s catalysts are sample-prep and oncology-assay demand, plus continued execution in a more selective diagnostics market. This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile. Better execution here can matter even before a new product or trial headline lands.

## Recent News
- 2024-11-27 21:05 EST — [QIAGEN führt neuartige Tools zur Anpassung von digitalen PCR‑Assays und NGS-Panels für die mikrobielle Analyse ein](https://biopharmsignal.com/news/QGEN/qiagen-f-hrt-neuartige-tools-zur-anpassung-von-digitalen-pcr-assays-und-ngs-pane-a242cf6d) — Source: Qiagen N.V.
- 2024-11-27 21:05 EST — [QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis](https://biopharmsignal.com/news/QGEN/qiagen-launches-novel-tools-for-customizing-digital-pcr-assays-and-ngs-panels-fo-1dbf1806) — Source: Qiagen N.V.
- 2024-11-12 21:05 EST — [QIAGEN und McGill University starten Partnerschaft zur Förderung der Mikrobiomforschung](https://biopharmsignal.com/news/QGEN/qiagen-und-mcgill-university-starten-partnerschaft-zur-f-rderung-der-mikrobiomfo-d8ea3ab3) — Source: Qiagen N.V.
- 2024-11-12 21:05 EST — [QIAGEN collaborates with McGill University to advance microbiome research](https://biopharmsignal.com/news/QGEN/qiagen-collaborates-with-mcgill-university-to-advance-microbiome-research-98e08ed5) — Source: Qiagen N.V.
- 2024-11-06 21:32 EST — [QIAGEN übertrifft Prognose für drittes Quartal 2024 mit solidem Wachstum und erhöht Jahresprognose für bereinigten Gewinn je Aktie](https://biopharmsignal.com/news/QGEN/qiagen-bertrifft-prognose-f-r-drittes-quartal-2024-mit-solidem-wachstum-und-erh--933db05e) — Source: Qiagen N.V.